379 related articles for article (PubMed ID: 18720710)
1. [Clinicopathogenetic features of coronary heart disease combined with chronic obstructive pulmonary diseases and efficiency of therapy with trimetazidin].
Kolomoets NM; Baksheev VI; Uvaĭsova KU
Klin Med (Mosk); 2008; 86(6):38-43. PubMed ID: 18720710
[TBL] [Abstract][Full Text] [Related]
2. Trimetazidine potentiates the effects of exercise training in patients with ischemic cardiomyopathy referred for cardiac rehabilitation.
Belardinelli R; Lacalaprice F; Faccenda E; Volpe L
Eur J Cardiovasc Prev Rehabil; 2008 Oct; 15(5):533-40. PubMed ID: 18797405
[TBL] [Abstract][Full Text] [Related]
3. [Peculiarities of the treatment of obstructive pulmonary disease in patients with combined pathology].
Klester EB; Shoĭkhet IaN
Klin Med (Mosk); 2009; 87(10):41-6. PubMed ID: 20017350
[TBL] [Abstract][Full Text] [Related]
4. [Potentialities of cytoprotection in the treatment of chronic heart failure in patients with coronary heart disease].
Fedorova TA; Il'ina IuV; Sotnikova TI; Rybakova MK
Klin Med (Mosk); 2004; 82(11):15-20. PubMed ID: 15656392
[TBL] [Abstract][Full Text] [Related]
5. Effect of trimetazidine on quality of life in elderly patients with ischemic dilated cardiomyopathy.
Marazzi G; Gebara O; Vitale C; Caminiti G; Wajngarten M; Volterrani M; Ramires JA; Rosano G; Fini M
Adv Ther; 2009 Apr; 26(4):455-61. PubMed ID: 19396409
[TBL] [Abstract][Full Text] [Related]
6. Effects of trimetazidine on myocardial perfusion and left ventricular systolic function in type 2 diabetic patients with ischemic cardiomyopathy.
Belardinelli R; Cianci G; Gigli M; Mazzanti M; Lacalaprice F
J Cardiovasc Pharmacol; 2008 Jun; 51(6):611-5. PubMed ID: 18574390
[TBL] [Abstract][Full Text] [Related]
7. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease.
Vitale C; Wajngaten M; Sposato B; Gebara O; Rossini P; Fini M; Volterrani M; Rosano GM
Eur Heart J; 2004 Oct; 25(20):1814-21. PubMed ID: 15474696
[TBL] [Abstract][Full Text] [Related]
8. The effects of trimetazidine on heart rate variability in patients with slow coronary artery flow.
Topal E; Ozdemir R; Barutcu I; Aksoy Y; Sincer I; Akturk E; Cehreli S
J Electrocardiol; 2006 Apr; 39(2):211-8. PubMed ID: 16580422
[TBL] [Abstract][Full Text] [Related]
9. [Intracardiac hemodynamics in patients with isolated chronic obstructive pulmonary disease and coronary heart disease].
Nevzorova VA; Golotina OV; Kochetkova EA; Ponomarenko IuV; Kessler R; Massard J
Klin Med (Mosk); 2010; 88(1):37-41. PubMed ID: 20369610
[TBL] [Abstract][Full Text] [Related]
10. [Heart rhythm disturbances in patients with chronic obstructive pulmonary disease in aggregate with coronary heart disease].
Shoĭkhet IaN; Klester EB; Golovin VA
Klin Med (Mosk); 2008; 86(3):21-6. PubMed ID: 18441699
[TBL] [Abstract][Full Text] [Related]
11. [Clinical outcomes of trimetazidine in patients with acute ST segment elevation myocardial infarction without ST segment resolution after primary percutaneous coronary intervention].
Peng JJ; Ma ZM; Ren WL; Ren LH; Lei LC; Liang Y
Zhonghua Yi Xue Za Zhi; 2009 May; 89(20):1399-401. PubMed ID: 19671333
[TBL] [Abstract][Full Text] [Related]
12. The effect of trimetazidine added to maximal anti-ischemic therapy in patients with advanced coronary artery disease.
Grabczewska Z; Białoszyński T; Szymański P; Sukiennik A; Swiatkiewicz I; Koziński M; Kochman W; Grześk G; Kubica J
Cardiol J; 2008; 15(4):344-50. PubMed ID: 18698543
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy of a cardioselective beta1-adrenoblocker bisoprolol in patients with chronic obstructive pulmonary disease in combination with ischemic heart disease].
Tsvetkova OA; Veselovskaia MV
Ter Arkh; 2007; 79(3):25-9. PubMed ID: 17526191
[TBL] [Abstract][Full Text] [Related]
14. [Chronic obstructive lung disease and coronary heart disease].
Karoli NA; Rebrov AP
Klin Med (Mosk); 2005; 83(6):72-6. PubMed ID: 16075651
[TBL] [Abstract][Full Text] [Related]
15. [Clinical and hemodynamic efficacy of selective beta-blocker bisoprolol and cytoprotector trimetazidine in the treatment of chronic cardiac failure in patients with ischemic heart disease].
Fedorova TA; Il'ina IuV; Sotnikova TI; Rybakova MK; Loshchits NV
Ter Arkh; 2004; 76(3):62-8. PubMed ID: 15108463
[TBL] [Abstract][Full Text] [Related]
16. Influence of diabetes mellitus on long-term survival in systematic off-pump coronary artery bypass surgery.
Marcheix B; Vanden Eynden F; Demers P; Bouchard D; Cartier R
Ann Thorac Surg; 2008 Oct; 86(4):1181-8. PubMed ID: 18805157
[TBL] [Abstract][Full Text] [Related]
17. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure.
Fragasso G; Palloshi A; Puccetti P; Silipigni C; Rossodivita A; Pala M; Calori G; Alfieri O; Margonato A
J Am Coll Cardiol; 2006 Sep; 48(5):992-8. PubMed ID: 16949492
[TBL] [Abstract][Full Text] [Related]
18. Beneficial effects of trimetazidine treatment on exercise tolerance and B-type natriuretic peptide and troponin T plasma levels in patients with stable ischemic cardiomyopathy.
Di Napoli P; Di Giovanni P; Gaeta MA; D'Apolito G; Barsotti A
Am Heart J; 2007 Sep; 154(3):602.e1-5. PubMed ID: 17719313
[TBL] [Abstract][Full Text] [Related]
19. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy.
Fragasso G; Piatti Md PM; Monti L; Palloshi A; Setola E; Puccetti P; Calori G; Lopaschuk GD; Margonato A
Am Heart J; 2003 Nov; 146(5):E18. PubMed ID: 14597947
[TBL] [Abstract][Full Text] [Related]
20. [Therapeutic value of trimetazidine in patients with coronary heart disease and left ventricular dysfunction].
Multicentral Collaborative Group on Trimetazidine (Phase IV)
Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Sep; 33(9):793-5. PubMed ID: 16266453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
